EVAX

$0.00

(

+0.00%

)
Quote details

stock

Evaxion Biotech AS

NASDAQ | EVAX

4.53

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 25, 2025)

$20.84M

Market Cap

-

P/E Ratio

-6.5

EPS

$16.10

52 Week High

$1.20

52 Week Low

HEALTHCARE

Sector

EVAX Chart

Recent Chart
Price Action

EVAX Technicals

Tags:

EVAX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.3M
Total Revenue $3.3M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$15M
Selling General And Administrative $7.3M
Research And Development $10M
Operating Expenses $18M
Investment Income Net -
Net Interest Income -$708K
Interest Income $254K
Interest Expense $962K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $607K
Income Before Tax -$11M
Income Tax Expense -$788K
Interest And Debt Expense -
Net Income From Continuing Operations -$11M
Comprehensive Income Net Of Tax -
Ebit -$10M
Ebitda -$9.8M
Net Income -$11M

Revenue & Profitability

Earnings Performance

EVAX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $12M
Total Current Assets $8.8M
Cash And Cash Equivalents At Carrying Value $5.1M
Cash And Short Term Investments $5.1M
Inventory -
Current Net Receivables $1.9M
Total Non Current Assets $3.7M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.9M
Other Non Current Assets -
Total Liabilities $14M
Total Current Liabilities $4.4M
Current Accounts Payable $3M
Deferred Revenue -
Current Debt -
Short Term Debt $473K
Total Non Current Liabilities $9.8M
Capital Lease Obligations $1.9M
Long Term Debt $8M
Current Long Term Debt $159K
Long Term Debt Noncurrent -
Short Long Term Debt Total $10M
Other Current Liabilities $927K
Other Non Current Liabilities -
Total Shareholder Equity -$1.7M
Treasury Stock -
Retained Earnings -$119M
Common Stock $11M
Common Stock Shares Outstanding $1.1M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$13M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $607K
Capital Expenditures $4.7
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$3K
Cashflow From Financing $13M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$11M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.3M
Total Revenue $3.3M
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$15M
Selling General And Administrative $7.3M
Research And Development $10M
Operating Expenses $18M
Investment Income Net -
Net Interest Income -$708K
Interest Income $254K
Interest Expense $962K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $607K
Income Before Tax -$11M
Income Tax Expense -$788K
Interest And Debt Expense -
Net Income From Continuing Operations -$11M
Comprehensive Income Net Of Tax -
Ebit -$10M
Ebitda -$9.8M
Net Income -$11M

EVAX News

EVAX Profile

Evaxion Biotech AS Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Evaxion Biotech AS (EVAX) is a clinical-stage biopharmaceutical company headquartered in Hørsholm, Denmark, specializing in the development of innovative immunotherapies through its cutting-edge artificial intelligence and immunology platform. The company is focused on addressing significant unmet medical needs in oncology, bacterial diseases, and viral infections by harnessing its proprietary technology to identify and design novel therapeutic candidates. As it advances its pipeline, Evaxion aims to revolutionize the treatment landscape and improve patient outcomes, positioning itself as a key player in the biotechnology sector.

PSTV
+39.28%
$0.56
DVLT
+45.33%
$0.94
INTC
+8.87%
$33.99
WOK
-22.40%
$0.08
SNAP
+1.33%
$8.33
CGBS
-39.47%
$0.03
NVDA
+0.40%
$177.69
RIG
-14.01%
$3.13
ATCH
+20.82%
$0.80
CIFR
-17.71%
$11.63
RGTI
+1.45%
$32.10
PEPG
+121.05%
$5.88
PLUG
-1.66%
$2.36
DNN
+3.45%
$2.84
TSLA
-4.38%
$423.39
AAL
-4.77%
$11.37
SPRC
+59.00%
$6.09
MARA
-8.90%
$16.07
IONZ
+10.37%
$4.05
YAAS
-5.55%
$0.10
NUAI
+49.83%
$1.38
EVAX
+37.27%
$4.53
NIO
+2.74%
$7.12
RAYA
-33.05%
$0.04
BITF
-3.42%
$2.68
SOUN
-8.04%
$16.35
TPIC
-45.91%
$0.12
FCX
-6.46%
$35.23
GRAB
+0.48%
$6.25
F
-0.12%
$11.61
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
QBTS
-4.97%
$26.34
KVUE
-4.12%
$16.16
TNFA
+48.14%
$5.20
IREN
-1.80%
$46.29
CPOP
+45.90%
$2.04
PFE
-2.01%
$23.60
ONDS
+6.05%
$7.79
AAPL
+1.80%
$256.87
LYT
-16.77%
$0.09
ETHD
+11.75%
$4.17
CAN
-10.64%
$0.79
WULF
-3.77%
$10.97
SOFI
-1.12%
$28.12
BMNR
-4.40%
$49.63
KDLY
+7.69%
$1.26
BTG
-1.62%
$4.84
TLRY
-4.76%
$1.20
STFS
+22.59%
$0.20
CRWV
-4.05%
$127.99
NAKA
+9.00%
$1.27
PLTR
-1.63%
$179.56
ABEV
+0.21%
$2.29
IONQ
-6.01%
$69.42
SLNH
+47.67%
$3.50
RIVN
-0.31%
$15.74
OKLO
-8.98%
$119.38
MRVL
+4.64%
$83.81
RXRX
-4.81%
$4.64
AMZN
-1.09%
$217.80
QUBT
-3.43%
$20.67
RMBL
+60.50%
$3.21
NOK
-1.37%
$4.67
ADAP
-6.27%
$0.12
ORCL
-5.55%
$291.33
BURU
-4.73%
$0.13
ADD
-25.47%
$0.05
ACHR
-3.57%
$9.36
BB
+8.54%
$4.63
CVE
-0.41%
$17.73
JOBY
-0.65%
$15.86
WBD
+0.05%
$19.82
QS
+0.84%
$12.59
NEHC
+9.00%
$0.92
SRM
+53.27%
$10.30
DEFT
-18.39%
$2.13
CLSK
-4.94%
$13.73
MU
-3.01%
$156.83
BTOC
+3.60%
$1.14
AMD
+0.29%
$161.36
RR
-7.14%
$4.09
ITUB
-1.41%
$7.18
ZONE
+20.20%
$2.38
HTZ
+0.86%
$7.03
HOOD
-3.35%
$122.55
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
ORIS
+11.64%
$0.30
HPE
-1.24%
$24.15
ETWO
0.00%
$3.30
LAES
+4.93%
$3.93
RIOT
-6.25%
$16.86
FSM
+1.60%
$8.55
IAG
+1.02%
$11.82
AG
+2.32%
$11.67
CLF
+2.89%
$12.07
APLD
-3.66%
$22.59
UUUU
+2.16%
$17.23
PSTV
+39.28%
$0.56
DVLT
+45.33%
$0.94
INTC
+8.87%
$33.99
WOK
-22.40%
$0.08
SNAP
+1.33%
$8.33
CGBS
-39.47%
$0.03
NVDA
+0.40%
$177.69
RIG
-14.01%
$3.13
ATCH
+20.82%
$0.80
CIFR
-17.71%
$11.63
RGTI
+1.45%
$32.10
PEPG
+121.05%
$5.88
PLUG
-1.66%
$2.36
DNN
+3.45%
$2.84
TSLA
-4.38%
$423.39
AAL
-4.77%
$11.37
SPRC
+59.00%
$6.09
MARA
-8.90%
$16.07
IONZ
+10.37%
$4.05
YAAS
-5.55%
$0.10
NUAI
+49.83%
$1.38
EVAX
+37.27%
$4.53
NIO
+2.74%
$7.12
RAYA
-33.05%
$0.04
BITF
-3.42%
$2.68
SOUN
-8.04%
$16.35
TPIC
-45.91%
$0.12
FCX
-6.46%
$35.23
GRAB
+0.48%
$6.25
F
-0.12%
$11.61
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
QBTS
-4.97%
$26.34
KVUE
-4.12%
$16.16
TNFA
+48.14%
$5.20
IREN
-1.80%
$46.29
CPOP
+45.90%
$2.04
PFE
-2.01%
$23.60
ONDS
+6.05%
$7.79
AAPL
+1.80%
$256.87
LYT
-16.77%
$0.09
ETHD
+11.75%
$4.17
CAN
-10.64%
$0.79
WULF
-3.77%
$10.97
SOFI
-1.12%
$28.12
BMNR
-4.40%
$49.63
KDLY
+7.69%
$1.26
BTG
-1.62%
$4.84
TLRY
-4.76%
$1.20
STFS
+22.59%
$0.20
CRWV
-4.05%
$127.99
NAKA
+9.00%
$1.27
PLTR
-1.63%
$179.56
ABEV
+0.21%
$2.29
IONQ
-6.01%
$69.42
SLNH
+47.67%
$3.50
RIVN
-0.31%
$15.74
OKLO
-8.98%
$119.38
MRVL
+4.64%
$83.81
RXRX
-4.81%
$4.64
AMZN
-1.09%
$217.80
QUBT
-3.43%
$20.67
RMBL
+60.50%
$3.21
NOK
-1.37%
$4.67
ADAP
-6.27%
$0.12
ORCL
-5.55%
$291.33
BURU
-4.73%
$0.13
ADD
-25.47%
$0.05
ACHR
-3.57%
$9.36
BB
+8.54%
$4.63
CVE
-0.41%
$17.73
JOBY
-0.65%
$15.86
WBD
+0.05%
$19.82
QS
+0.84%
$12.59
NEHC
+9.00%
$0.92
SRM
+53.27%
$10.30
DEFT
-18.39%
$2.13
CLSK
-4.94%
$13.73
MU
-3.01%
$156.83
BTOC
+3.60%
$1.14
AMD
+0.29%
$161.36
RR
-7.14%
$4.09
ITUB
-1.41%
$7.18
ZONE
+20.20%
$2.38
HTZ
+0.86%
$7.03
HOOD
-3.35%
$122.55
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
ORIS
+11.64%
$0.30
HPE
-1.24%
$24.15
ETWO
0.00%
$3.30
LAES
+4.93%
$3.93
RIOT
-6.25%
$16.86
FSM
+1.60%
$8.55
IAG
+1.02%
$11.82
AG
+2.32%
$11.67
CLF
+2.89%
$12.07
APLD
-3.66%
$22.59
UUUU
+2.16%
$17.23

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.